Most recdntly enrolled at the top
Individualized immunosuppression in kidney transplanted patients
Katrine Agergaard Sørensen
The PhD project aims to investigate if the anti-rejection treatment of patients with a kidney transplant can be improved, which might lead to fewer kidney rejections and a longer life span of transplanted kidneys.
The anti-rejection medicine tacrolimus is necessary to prevent kidney rejection and it is routine to measure tacrolimus in all patients’ blood at regular intervals and to adjust the dose accordingly to minimize adverse events and organ rejection. We want to investigate if tacrolimus measured inside the immune cells in the blood is a much better measure of how tacrolimus is affecting the body in order to individualize the treatment more in the future.
Main supervisor: Troels K. Bergmann
Prenatal and early life PFAS exposure; impact on neuropsychological and neurophysiological development in 1.5- to 7-year-old children in Odense Child Cohort.
Iben Have Beck
Perfluoroalkyl acids (PFAAs) are widely used persistent chemicals with water and oil repellent properties. Humans are exposed through ingestion and inhalation. PFAAs can cross the placenta and expose the developing foetus. The foetal brain is especially vulnerable due to rapid growth and exposure to PFAA during critical time windows may have long term impact. Preliminary findings from Odense Child cohort (OCC) suggest that prenatal exposure to PFOS is associated with reduced vocabulary in young boys. These findings are of concern as language development is a marker of later school performance. It is important to investigate whether these adverse effects are persisting, which is possible in OCC where mothers were enrolled in early pregnancy and offspring are followed intensively with repeated clinical examinations.
We aim to investigate the impact of prenatal and early life exposure to PFAAs on neurodevelopment including language development, motor skills and IQ-score in 1.5 to 7-year-old children.
Main supervisor: Tina Kold Jensen
Frederik Damsgaard Højsager
Supporting safe use of antibiotics: Penicillinase-resistant penicillins as inducers of drug metabolism and drug transporters
Ditte Bork Iversen
This project aims to support the safe and rational use of the penicillinase-resistant antibiotics, dicloxacillin and flucloxacillin. We will perform two clinical studies and one register-based study. The clinical studies will elucidate if flucloxacillin increases drug metabolism in healthy volunteers and if dicloxacillin causes drug-drug interactions through induction of drug transporters. Furthermore, we will determine whether dicloxacillin and flucloxacillin induce their own metabolism potentially causing reduced antimicrobial efficacy over time. The register-based study will investigate the clinical relevance of the inductive potentials of dicloxacillin and flucloxacillin by assessing a potential increased risk of ischemic stroke or systemic embolism in patients on oral anticoagulants when treated with these antibiotics.
Main supervisor: Tore Bjerregaard Stage
Ida Berglund Kuhlmann
Big-data screening for undiscovered drug-outcome associations
Lars Christian Lund
Traditional pharmacovigilance is based on the reporting of suspected adverse drug reactions (ADRs), although this is severely limited by underreporting. Epidemiological screening of health-care databases for drug-outcome associations has been proposed as an alternative.
In this project we aim to improve upon the existing methods of epidemiological pharmacovigilance by conducting two studies, each addressing a type of ADR that is difficult to detect by traditional and epidemiological PV: 1) A study screening all marketed drugs for an adverse outcome occurring during ongoing therapy, using a symmetry analysis design, with drug-induced diabetes serving as a prototype. 2) A study screening all marketed drugs for adverse outcomes related to long-term cumulative exposure. Nested case-control studies will be conducted for every combination of drugs and diagnoses. An algorithm for priority assignment of the signals generated in this study will also be developed.
Main supervisor: Jesper Hallas
Molecular mechanisms and drug transport in chemotherapy-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect to several chemotherapeutic drugs. There is currently no effective treatment of this side effect, leaving dose adjustment as the only possibility. Dose reduction limits the clinical efficacy of chemotherapy and cause a substantial reduction in treatment success. In the development of CIPN, sensory neurons of the peripheral nervous system are the cell type primarily affected by chemotherapeutic drugs. When dysfunctional, patients experience intolerable symptoms such as burning pain, numbness and sensory loss in hands and feet. These studies are expected to provide insight to the effect of chemotherapy on sensory neurons and investigate a novel biomarker for neuronal damage in a translational setting. The results may lead to discovery of novel drug targets to treat or prevent CIPN and ultimately may be useful in helping diagnose and monitor cancer patients with CIPN.
Main supervisor: Tore Bjerregaard Stage
Use of Real-World Data in screening for unknown drug effects and drug utilisation patterns within dermatology
Monitoring of marketed drugs is an important part of the ongoing evaluation of the benefits and risks of drugs, and epidemiological analyzes of healthcare data have been proposed as an alternative to traditional side-effect monitoring.
In this project, epidemiologic screening of large healthcare databases will be applied to evaluate its use within dermatology, by conducting: 1) A study screening all dermatology drugs for adverse and beneficial effects, by using self-controlled designs and a nested case-control analysis. 2) A study screening all marketed drugs for dermatological adverse outcomes using the same designs. 3) A comprehensive dermatology drug utilisation study screening for unexpected utilisation patterns.
Main supervisor: Jesper Hallas
Public Health Research in the Danish Community Pharmacy setting
Alaa Hassan Burghle
In Denmark, patients can go to any community pharmacy, with no appointment, and receive counselling on the safe and effective use of medication. In addition to the usual counselling a number of pharmaceutical care services are provided. This setting makes the community pharmacy an excellent data-provider for research projects as its platform can e.g. be used to collect information from patients on side effects not otherwise available through other means or targeting inappropriate use of medications through pharmaceutical care. With this PhD-thesis we aim to further explore and strengthen the possibility of conducting public health research projects in the Danish community pharmacy setting. We will achieve this through the conduct of three research projects, each utilizing different methods: a randomized controlled trial, a qualitative study, and a survey.
Main Supervisor: Anton Pottegård
The effect of initiating glucose-lowering treatment on the metabolism, transport and efficacy of other drugs among patients with type 2 diabetes
Ann-Cathrine Dalgård Dunvald
We have previously shown that initiation of glucose-lowering treatment leads to altered drug efficacy. To further elucidate this surprising but potentially impactful finding, we will assess the effect of glucose on the activity of important drug-metabolizing enzymes and transporters. Clinical pharmacokinetic studies in patients with type 2 diabetes will uncover the pharmacokinetic extent of this effect. Two different drug cocktails (one assessing drug-metabolizing enzyme activity and another assessing drug transport) will be administered to patients before and after initiation of the glucose-lowering drug metformin. This will uncover whether lowering of glucose causes altered drug metabolism and transport in patients with type 2 diabetes. Extensive register-based studies will elucidate the direct clinical impact of this effect. The knowledge obtained in these studies will help guide clinical decisions for managing comedication when initiating glucose-lowering treatment for patients with type 2 diabetes and provide a deeper understand of interindividual variability of drug metabolism.
Main Supervisor: Tore Bjerregaard Stage
Implementation of personalized medicine in everyday practice: Preventing serious adverse reactions from chemotherapy.
Niels Herluf Paulsen
This project aims to substantially reduce the risk of serious adverse reactions in patients receiving 5-fluorouracil (5-FU) for cancer. The project will use a gene test to preemptively adjust the dose of 5-FU for each patient and hereby reducing the risk of risk of severe adverse reactions. This project may serve as a proof-of-concept for implementation of personalized medicine in everyday cancer treatment.
Main supervisor: Per Damkier
Pharmacoepidemiological aspects of low-dose or off-label treatment with antipsychotics: Utilization and consequences
This PhD project uses register data to explore diagnoses associated with use of antipsychotics (psychiatric and non-psychiatric), and furthermore to investigate the potential acute and long-term risks associated with low-dose antipsychotic treatment.
Main supervisor: Jesper Hallas
Attitudes towards deprescribing in older patients with limited life expectancy: The perspective of patients, relatives, and health care professionals
This PhD project aims to explore attitudes towards deprescribing from the perspective of patients, relatives, and health care professionals, specifically focusing on older people with frailty and those approaching the last part of life. We will do this through systematic reviews and qualitative studies. Further, we will translate, cross-culturally adapt, and validate a questionnaire for exploring patient attitudes towards deprescribing. With this PhD project, we aim to get insight into what may facilitate and hinder deprescribing, and thus how to ultimately improve the uptake of deprescribing in clinical practice.
Main supervisor: Anton Pottegård
CYP2D6 genotype-phenotype determination for improved personalized medicine
The objective of this project is to establish the clinical function level of the most frequent CYP2D6 alleles through population pharmacokinetic modelling of different CYP2D6 substrates. Ultimately, the aim is to find an optimal method for translating CYP2D6 genotypes into phenotypes for improved personalized medicine. The project is conducted in collaboration with H. Lundbeck A/S.
Main supervisor: Kim Brøsen
Co-supervisor: Tore Bjerregaard Stage